Vai ai contenuti. | Spostati sulla navigazione | Spostati sulla ricerca | Vai al menu | Contatti | Accessibilità

| Crea un account

Giuliani, Luisa (2008) Expression and functional role of Urotesin-II and its receptor in the adrenal cortex and medulla. [Tesi di dottorato]

Full text disponibile come:

Documento PDF

Abstract (inglese)

Numerous paracrine interactions between the adrenal cortex and medulla are likely to play a role in the pathogenesis of pheochromocytoma (PHEO) and aldosterone-producing adenoma (APA). Nonetheless, the mechanisms underlying excess production of catecholamines in PHEO and of aldosterone in APA are complex and largely unknown.
Urotensin II (UII) is a vasoactive peptide that acts through specific G protein-coupled receptor (GPR)-14, named UT-R, and is widely expressed in tissues, including the vasculature and the rat and human adrenal gland. Along with the detection of UII and UT-R gene transcripts in APA and PHEO, these findings led to propose a role of the UII in adrenal gland pathophysiology and, therefore, in the regulation of blood pressure and body fluid homeostasis. However, the quantitative expression of UII and UT-R in APA and PHEO and the biological effects of UII in the adrenal gland remained poorly known. Novel techniques may provide powerful investigative tools to shed new light on the molecular complexity of adrenal tumors. Hence, we used real-time RT-PCR and a whole transcriptome analysis to pinpoint UII and UT-R related pathways in adrenocortical and adreno-medullary tumors and to precisely quantify the UII and UT-R transcripts in APA and PHEO. We next sought for the UII peptide by Western blot analysis and immunohistochemistry. Recently, UT-R antagonists have been prepared and this can enable investigators to directly address the role played by UII and its receptors in different pathophysiological conditions.
Moreover, we took advantage of the recent development of palosuran, a specific UT-R antagonist, to investigate the role of UT-R activation on the adrenocortical expression of aldosterone synthase (CYP11B2) and 11? hydroxylase (CYP11B1) by means of a chronic UII infusion on the rat adrenal gland.

Statistiche Download - Aggiungi a RefWorks
Tipo di EPrint:Tesi di dottorato
Relatore:Rossi, Gian Paolo
Dottorato (corsi e scuole):Ciclo 20 > Corsi per il 20simo ciclo > IPERTENSIONE ARTERIOSA E BIOLOGIA VASCOLARE
Data di deposito della tesi:08 Marzo 2008
Anno di Pubblicazione:08 Marzo 2008
Parole chiave (italiano / inglese):Urotensin II, Urotensin II receptor, adrenal cortex, aldosterone-producing adenoma, medulla, pheochromocytoma, humans
Settori scientifico-disciplinari MIUR:Area 06 - Scienze mediche > MED/09 Medicina interna
Struttura di riferimento:Dipartimenti > Dipartimento di Medicina Clinica e Sperimentale
Codice ID:179
Depositato il:24 Ott 2008
Simple Metadata
Full Metadata
EndNote Format


I riferimenti della bibliografia possono essere cercati con Cerca la citazione di AIRE, copiando il titolo dell'articolo (o del libro) e la rivista (se presente) nei campi appositi di "Cerca la Citazione di AIRE".
Le url contenute in alcuni riferimenti sono raggiungibili cliccando sul link alla fine della citazione (Vai!) e tramite Google (Ricerca con Google). Il risultato dipende dalla formattazione della citazione.

1. Rainey WE. Adrenal zonation: clues from 11beta-hydroxylase and aldosterone synthase. Mol Cell Endocrinol. 1999;151:151-160. Cerca con Google

2. CONN JW. Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med. 1955;45:3-17. Cerca con Google

3. Rossi GP, Bernini G, Caliumi C et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006;48:2293-2300. Cerca con Google

4. Rossi GP. New concepts in adrenal vein sampling for aldosterone in the diagnosis of primary aldosteronism. Curr Hypertens Rep. 2007;9:90-97. Cerca con Google

5. Omura M, Saito J, Yamaguchi K et al. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res. 2004;27:193-202. Cerca con Google

6. Rossi GP, Bernini G, Desideri G et al. Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension. 2006;48:232-238. Cerca con Google

7. Rossi GP, Di B, V, Ganzaroli C et al. Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension. 2002;40:23-27. Cerca con Google

8. Rocha R, Funder JW. The pathophysiology of aldosterone in the cardiovascular system. Ann N Y Acad Sci. 2002;970:89-100. Cerca con Google

9. Rossi GP, Pessina AC, Heagerty AM. Primary aldosteronism: an update on screening, diagnosis and treatment. Journal of Hypertension. 2008;26. Cerca con Google

10. Schwartz GL, Turner ST. Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem. 2005;51:386-394. Cerca con Google

11. Whalen RK, Althausen AF, Daniels GH. Extra-adrenal pheochromocytoma. J Urol. 1992;147:1-10. Cerca con Google

12. Pacak K, Linehan WM, Eisenhofer G et al. Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med. 2001;134:315-329. Cerca con Google

13. Coupland R. The natural history of the chromaffin cell. Essex, UK: Longsman Green and Co. 1965. Cerca con Google

14. Erickson D, Kudva YC, Ebersold MJ et al. Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients. J Clin Endocrinol Metab. 2001;86:5210-5216. Cerca con Google

15. Anderson GH, Jr., Blakeman N, Streeten DH. The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens. 1994;12:609-615. Cerca con Google

16. Sinclair AM, Isles CG, Brown I et al. Secondary hypertension in a blood pressure clinic. Arch Intern Med. 1987;147:1289-1293. Cerca con Google

17. Stenstrom G, Svardsudd K. Pheochromocytoma in Sweden 1958-1981. An analysis of the National Cancer Registry Data. Acta Med Scand. 1986;220:225-232. Cerca con Google

18. Beard CM, Sheps SG, Kurland LT et al. Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc. 1983;58:802-804. Cerca con Google

19. Hartley L, Perry-Keene D. Phaeochromocytoma in Queensland--1970-83. Aust N Z J Surg. 1985;55:471-475. Cerca con Google

20. Andersen GS, Toftdahl DB, Lund JO et al. The incidence rate of phaeochromocytoma and Conn's syndrome in Denmark, 1977-1981. J Hum Hypertens. 1988;2:187-189. Cerca con Google

21. Fernandez-Calvet L, Garcia-Mayor RV. Incidence of pheochromocytoma in South Galicia, Spain. J Intern Med. 1994;236:675-677. Cerca con Google

22. Lo CY, Lam KY, Wat MS et al. Adrenal pheochromocytoma remains a frequently overlooked diagnosis. Am J Surg. 2000;179:212-215. Cerca con Google

23. Neumann HP, Bausch B, McWhinney SR et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med. 2002;346:1459-1466. Cerca con Google

24. Plouin PF, Gimenez-Roqueplo AP. Initial work-up and long-term follow-up in patients with phaeochromocytomas and paragangliomas. Best Pract Res Clin Endocrinol Metab. 2006;20:421-434. Cerca con Google

25. Amar L, Bertherat J, Baudin E et al. Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol. 2005;23:8812-8818. Cerca con Google

26. Gimm O, Koch CA, Januszewicz A et al. The genetic basis of phechromocytoma. Front Horm Res. 2004;31:45-60. Cerca con Google

27. Bravo EL, Tagle R. Pheochromocytoma: state-of-the-art and future prospects. Endocr Rev. 2003;24:539-553. Cerca con Google

28. Mantero F, Terzolo M, Arnaldi G et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab. 2000;85:637-644. Cerca con Google

29. Montemurro D, Rossi GP. Veralipride-induced acute coronary syndrome unmasking a non-secreting pheochromocytoma. J Endocrinol Invest. 2006;29:650-652. Cerca con Google

30. Bernini GP, Moretti A, Ferdeghini M et al. A new human chromogranin 'A' immunoradiometric assay for the diagnosis of neuroendocrine tumours. Br J Cancer. 2001;84:636-642. Cerca con Google

31. Boomsma F, Bhaggoe UM, Man in 't Veld AJ et al. Sensitivity and specificity of a new ELISA method for determination of chromogranin A in the diagnosis of pheochromocytoma and neuroblastoma. Clin Chim Acta. 1995;239:57-63. Cerca con Google

32. Canale MP, Bravo EL. Diagnostic specificity of serum chromogranin-A for pheochromocytoma in patients with renal dysfunction. J Clin Endocrinol Metab. 1994;78:1139-1144. Cerca con Google

33. Rossi GP, Seccia TM, Pessina AC. Clinical use of laboratory tests for the identification of secondary forms of arterial hypertension. Crit Rev Clin Lab Sci. 2007;44:1-85. Cerca con Google

34. Kleitman N, Holzwarth MA. Catecholaminergic innervation of the rat adrenal cortex. Cell Tissue Res. 1985;241:139-147. Cerca con Google

35. Palacios G, Lafarga M. Chromaffin cells in the glomerular zone of adult rat adrenal cortex. Cell Tissue Res. 1975;164:275-278. Cerca con Google

36. Vinson GP, Hinson JP, Toth IE. The neuroendocrinology of the adrenal cortex. J Neuroendocrinol. 1994;6:235-246. Cerca con Google

37. Vizi ES, Toth IE, Szalay KS et al. Catecholamines released from local adrenergic axon terminals are possibly involved in fine tuning of steroid secretion from zona glomerulosa cells: functional and morphological evidence. J Endocrinol. 1992;135:551-561. Cerca con Google

38. Toth IE, Hinson JP. Neuropeptides in the adrenal gland: distribution, localization of receptors, and effects on steroid hormone synthesis. Endocr Res. 1995;21:39-51. Cerca con Google

39. Vinson GP, Hinson JP. Blood flow and hormone secretion in the adrenal gland. Ravenn Press, New York , 71-86. 1992. Vinson GP, 71-86,1992. 1992. Cerca con Google

40. Mulrow PJ. Adrenal renin: regulation and function. Front Neuroendocrinol. 1992;13:47-60. Cerca con Google

41. Nussdorfer GG, Rossi GP, Belloni AS. The role of endothelins in the paracrine control of the secretion and growth of the adrenal cortex. Int Rev Cytol. 1997;171:267-308. Cerca con Google

42. Neri G, Andreis PG, Prayer-Galetti T et al. Pituitary adenylate-cyclase activating peptide enhances aldosterone secretion of human adrenal gland: evidence for an indirect mechanism, probably involving the local release of catecholamines. J Clin Endocrinol Metab. 1996;81:169-173. Cerca con Google

43. Kawamura M, Nakamichi N, Imagawa N et al. Effect of adrenaline on steroidogenesis in primary cultured bovine adrenocortical cells. Jpn J Pharmacol. 1984;36:35-41. Cerca con Google

44. Ehrhart-Bornstein M, Bornstein S.R., Trzeciak W.H. et al. Adrenaline stimulates cholesterol side-chain cleavage cytochrome P450 mRNA accumulation in bovine adrenocortical cells. J Endocrinol. 1991;131:R5-R8(Ehrhart-bornstein m, 1991b, 131-r5-r8). Cerca con Google

45. Gallo-Payet N, Chouinard L, Balestre MN et al. Dual effects of dopamine in rat adrenal glomerulosa cells. Biochem Biophys Res Commun. 1990;172:1100-1108. Cerca con Google

46. Matsuoka H, Ishii M, Goto A et al. Role of serotonin type 2 receptors in regulation of aldosterone production. Am J Physiol. 1985;249:E234-E238. Cerca con Google

47. Holzwarth MA, Brownfield MS. Serotonin coexists with epinephrine in rat adrenal medullary cells. Neuroendocrinology. 1985;41:230-236. Cerca con Google

48. Bern HA, Pearson D, Larson BA et al. Neurohormones from fish tails: the caudal neurosecretory system. I. "Urophysiology" and the caudal neurosecretory system of fishes. Recent Prog Horm Res. 1985;41:533-552. Cerca con Google

49. Pearson D, Shively JE, Clark BR et al. Urotensin II: a somatostatin-like peptide in the caudal neurosecretory system of fishes. Proc Natl Acad Sci U S A. 1980;77:5021-5024. Cerca con Google

50. Coulouarn Y, Lihrmann I, Jegou S et al. Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proc Natl Acad Sci U S A. 1998;95:15803-15808. Cerca con Google

51. Douglas SA, Ohlstein EH. Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. Trends Cardiovasc Med. 2000;10(6):229-237. Cerca con Google

52. Russell FD, Kearns P, Toth I et al. Urotensin-II-converting enzyme activity of furin and trypsin in human cells in vitro. J Pharmacol Exp Ther. 2004;310:209-214. Cerca con Google

53. Ames RS, Sarau HM, Chambers JK et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature. 1999;401:282-286. Cerca con Google

54. Sauzeau V, Le Mellionnec E, Bertoglio J et al. Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase. Circ Res. 2001;88:1102-1104. Cerca con Google

55. Maguire JJ, Kuc RE, Davenport AP. Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br J Pharmacol. 2000;131:441-446. Cerca con Google

56. Stirrat A, Gallagher M, Douglas SA et al. Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries. Am J Physiol Heart Circ Physiol. 2001;280:H925-H928. Cerca con Google

57. Douglas SA, Tayara L, Ohlstein EH et al. Congestive heart failure and expression of myocardial urotensin II. Lancet. 2002;359:1990-1997. Cerca con Google

58. Gibson A. Complex effects of Gillichthys urotensin II on rat aortic strips. Br J Pharmacol. 1987;91:205-212. Cerca con Google

59. Bottrill FE, Douglas SA, Hiley CR et al. Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries. Br J Pharmacol. 2000;130:1865-1870. Cerca con Google

60. Maguire JJ, Davenport AP. Is urotensin-II the new endothelin? Br J Pharmacol. 2002;137:579-588. Cerca con Google

61. Ishihata A, Ogaki T, Aita T et al. Role of prostaglandins in urotensin II-induced vasodilatation in the coronary arteries of aged rats. Eur J Pharmacol. 2005;523:119-126. Cerca con Google

62. Douglas SA, Sulpizio AC, Piercy V et al. Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol. 2000;131:1262-1274. Cerca con Google

63. Behm DJ, Harrison SM, Ao Z et al. Deletion of the UT receptor gene results in the selective loss of urotensin-II contractile activity in aortae isolated from UT receptor knockout mice. Br J Pharmacol. 2003;139:464-472. Cerca con Google

64. Giebing G, Tolle M, Jurgensen J et al. Arrestin-independent internalization and recycling of the urotensin receptor contribute to long-lasting urotensin II-mediated vasoconstriction. Circ Res. 2005;97:707-715. Cerca con Google

65. Saetrum OO, Nothacker H, Ehlert FJ et al. Human urotensin II mediates vasoconstriction via an increase in inositol phosphates. Eur J Pharmacol. 2000;406:265-271. Cerca con Google

66. Tasaki K, Hori M, Ozaki H et al. Mechanism of human urotensin II-induced contraction in rat aorta. J Pharmacol Sci. 2004;94:376-383. Cerca con Google

67. Rossowski WJ, Cheng BL, Taylor JE et al. Human urotensin II-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase: inhibition by somatostatin receptor antagonists. Eur J Pharmacol. 2002;438:159-170. Cerca con Google

68. Spinazzi R, Albertin G, Nico B et al. Urotensin-II and its receptor (UT-R) are expressed in rat brain endothelial cells, and urotensin-II via UT-R stimulates angiogenesis in vivo and in vitro. Int J Mol Med. 2006;18:1107-1112. Cerca con Google

69. Clozel M, Binkert C, Birker-Robaczewska M et al. Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl) -urea sulfate salt): first demonstration of a pathophysiological role of the urotensin System. J Pharmacol Exp Ther. 2004;311:204-212. Cerca con Google

70. Totsune K, Takahashi K, Arihara Z et al. Increased plasma urotensin II levels in patients with diabetes mellitus. Clin Sci (Lond). 2003;104:1-5. Cerca con Google

71. Totsune K, Takahashi K, Arihara Z et al. Role of urotensin II in patients on dialysis. Lancet. 2001;358:810-811. Cerca con Google

72. Dschietzig T, Bartsch C, Pregla R et al. Plasma levels and cardiovascular gene expression of urotensin-II in human heart failure. Regul Pept. 2002;110:33-38. Cerca con Google

73. Matsushita M, Shichiri M, Imai T et al. Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. J Hypertens. 2001;19:2185-2190. Cerca con Google

74. Ng LL, Loke I, O'Brien RJ et al. Plasma urotensin in human systolic heart failure. Circulation. 2002;106:2877-2880. Cerca con Google

75. Richards AM, Nicholls MG, Lainchbury JG et al. Plasma urotensin II in heart failure. Lancet. 2002;360:545-546. Cerca con Google

76. Totsune K, Takahashi K, Arihara Z et al. Elevated plasma levels of immunoreactive urotensin II and its increased urinary excretion in patients with Type 2 diabetes mellitus: association with progress of diabetic nephropathy. Peptides. 2004;25:1809-1814. Cerca con Google

77. Johns DG, Ao Z, Naselsky D et al. Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators. Naunyn Schmiedebergs Arch Pharmacol. 2004;370:238-250. Cerca con Google

78. Birker-Robaczewska M, Boukhadra C, Studer R et al. The expression of urotensin II receptor (U2R) is up-regulated by interferon gamma. J Recept Signal Transduct Res. 2003;23:289-305. Cerca con Google

79. Mallamaci F, Cutrupi S, Pizzini P et al. Urotensin II in end-stage renal disease: an inverse correlate of sympathetic function and cardiac natriuretic peptides. J Nephrol. 2005;18:727-732. Cerca con Google

80. Watanabe T, Pakala R, Katagiri T et al. Synergistic effect of urotensin II with mildly oxidized LDL on DNA synthesis in vascular smooth muscle cells. Circulation. 2001;104:16-18. Cerca con Google

81. Tamura K, Okazaki M, tamura m et al. Urotensin II-induced activation of extracellular signal-regulated kinase in cultured vascular amooth muscle cells: involvement of cell adhesion-mediated integrin signaling. Life Sci. 2003;72:1049-1060. Cerca con Google

82. Takahashi K, Totsune K, Murakami O et al. Expression of urotensin II and its receptor in adrenal tumors and stimulation of proliferation of cultured tumor cells by urotensin II. Peptides. 2003;24:301-306. Cerca con Google

83. Takahashi K, Totsune K, Murakami O et al. Expression of urotensin II and urotensin II receptor mRNAs in various human tumor cell lines and secretion of urotensin II-like immunoreactivity by SW-13 adrenocortical carcinoma cells. Peptides. 2001;22:1175-1179. Cerca con Google

84. Zeng ZP, Liu GQ, Li HZ et al. The effects of urotensin-II on proliferation of pheochromocytoma cells and mRNA expression of urotensin-II and its receptor in pheochromocytoma tissues. Ann N Y Acad Sci. 2006;1073:284-289. Cerca con Google

85. Albertin G, Casale V, Ziolkowska A et al. Urotensin-II and UII-receptor expression and function in the rat adrenal cortex. Int J Mol Med. 2006;17:1111-1115. Cerca con Google

86. Nussdorfer GG. Paracrine control of adrenal cortical function by medullary chromaffin cells. Pharmacol Rev. 1996;48:495-530. Cerca con Google

87. Lenzini L, Seccia TM, Aldighieri E et al. Heterogeneity of aldosterone-producing adenomas revealed by a whole transcriptome analysis. Hypertension. 2007;50:1106-1113. Cerca con Google

88. Rossi G, Albertin G, Belloni A et al. Gene expression, localization, and characterization of endothelin A and B receptors in the human adrenal cortex. J Clin Invest. 1994;94:1226-1234. Cerca con Google

89. Rossi GP, Sacchetto A, Chiesura-Corona M et al. Identification of the etiology of primary aldosteronism with adrenal vein sampling in patients with equivocal computed tomography and magnetic resonance findings: results in 104 consecutive cases. J Clin Endocrinol Metab. 2001;86:1083-1090. Cerca con Google

90. 1999 World Health Organization. International Society of Hypertension Guidelines for the management of Hypertension. Guidelines Subcommittee. J Hypertens. 1999;17:151-183. Cerca con Google

91. Ashburner M, Ball CA, Blake JA et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000;25:25-29. Cerca con Google

92. Rossi GP, Sticchi D, Giuliani L et al. Adiponectin receptor expression in the human adrenal cortex and aldosterone-producing adenomas. Int J Mol Med. 2006;17:975-980. Cerca con Google

93. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)). Methods. 2001;25:402-408. Cerca con Google

94. Lowry OH, Rosebrough TD, Farr AL et al. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:165-175. Cerca con Google

95. Antonello M, Montemurro D, Bolognesi M et al. Prevention of hypertension, cardiovascular damage and endothelial dysfunction with green tea extracts. Am J Hypertens. 2007;20:1321-1328. Cerca con Google

96. MacKenzie SM, Clark CJ, Fraser R et al. Expression of 11beta-hydroxylase and aldosterone synthase genes in the rat brain. J Mol Endocrinol. 2000;24:321-328. Cerca con Google

97. Imbeaud S, Graudens E, Boulanger V et al. Towards standardization of RNA quality assessment using user-independent classifiers of microcapillary electrophoresis traces. Nucleic Acids Res. 2005;33:e56. Cerca con Google

98. Watson AM, May CN. Urotensin II, a novel peptide in central and peripheral cardiovascular control. Peptides. 2004;25:1759-1766. Cerca con Google

99. Boucard AA, Sauve SS. Photolabelling the rat urotensin II/GPR14 receptor identifies a ligand-binding site in the fourth transmembrane domain. Biochem J. 2003;370:829-838. Cerca con Google

100. Gordon RD, Bachmann AW, Klemm SA et al. An association of primary aldosteronism and adrenaline-secreting phaeochromocytoma. Clin Exp Pharmacol Physiol. 1994;21:219-222. Cerca con Google

101. Kitajima W, Saruta T, Kondo K et al. A case of secondary aldosteronism induced by pheochromocytoma. J Urol. 1975;114:141-143. Cerca con Google

102. Mannhart M, Ludin H, Veyrat R et al. Secondary hyperaldosteronism caused by cervical phaeochromocytoma cured by ablation of the tumor. Helv Med Acta. 1971;35:479-483. Cerca con Google

103. Tan GH, Carney JA, Grant CS et al. Coexistence of bilateral adrenal phaeochromocytoma and idiopathic hyperaldosteronism. Clin Endocrinol (Oxf). 1996;44:603-609. Cerca con Google

104. Wajiki M, Ogawa A, Fukui J et al. Coexistence of aldosteronoma and pheochromocytoma in an adrenal gland. J Surg Oncol. 1985;28:75-78. Cerca con Google

105. Kamba S, Yukawa, Kato D et al. A case report of primary aldosteronism combined with pheochromocytoma, struma nodosa and aneurysm of the abdominal aorta. Geka Chiryo. 1978;38:491-497. Cerca con Google

Download statistics

Solo per lo Staff dell Archivio: Modifica questo record